ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.

eCancerMedicalScience, a leading open-access journal published by the eCancer Global Foundation, is dedicated to advancing the field of cancer research and oncology. With its inception in 2007, this esteemed journal has emerged as a pivotal platform for disseminating groundbreaking research, innovative treatments, and comprehensive reviews in the cancer domain. Based in the United Kingdom, eCancerMedicalScience has continuously contributed to the academic community with its rigorous peer-review process and broad-ranging scope, now encompassing topics from clinical oncology to molecular biology. Currently ranked in the Q3 quartile for both Cancer Research and Oncology in 2023, the journal provides a significant opportunity for researchers, professionals, and students to access valuable insights and share their findings within a global network. The commitment to open access ensures that knowledge is readily available, fostering collaborative efforts to combat cancer and improve patient outcomes.

Journal of Thoracic Oncology, published by Elsevier Science Inc, is a premier scholarly outlet dedicated to advancing the field of thoracic oncology. With an impressive impact factor and consistently rated in the Q1 quartile across several pertinent categories such as Medicine, Oncology, and Pulmonary and Respiratory Medicine, this journal stands at the forefront of research dissemination. Covering a broad scope that includes innovative therapeutic approaches, clinical trials, and the molecular underpinnings of thoracic malignancies, the journal serves as a vital resource for researchers, healthcare professionals, and students seeking to enhance their understanding of thoracic cancer and its treatment. With publication dates converging from 2006 to 2024, the Journal of Thoracic Oncology fosters a collaborative scholarly community by providing a platform for high-quality research while ensuring accessibility through traditional publication formats. Positioned in the heart of New York City, this journal not only reflects the cutting-edge advancements in oncology but also plays a pivotal role in shaping the future of thoracic cancer care.

Clinical Lymphoma Myeloma & Leukemia is a prestigious journal dedicated to the study and treatment of hematologic malignancies, offering a vital platform for researchers and healthcare professionals in the fields of oncology, hematology, and cancer research. Published by CIG MEDIA GROUP, LP, this journal has established itself as a crucial resource since its inception in 2010, with a continuous commitment to disseminating knowledge until at least 2024. With an impact factor that objectively reflects its influence, it is rated in Q3 quartiles in both Cancer Research and Hematology as well as in Oncology as of 2023. Researchers can access a wealth of articles and studies that explore various dimensions of lymphoma, myeloma, and leukemia, thus fostering an environment of collaboration and innovation. Although it currently does not offer full open access, its extensive archive and rigorous peer-review process ensure the publication of high-quality research, making it an essential resource for anyone dedicated to advancing the science and practice of treating blood cancers.

Breast Care is a prominent academic journal published by KARGER, focusing on the dynamic fields of oncology and surgery. With an ISSN of 1661-3791 and an E-ISSN of 1661-3805, this peer-reviewed journal has established itself as an essential resource for researchers, clinicians, and students dedicated to advancing breast health. Based in Switzerland, it benefits from a strong academic reputation, evident in its impressive Scopus rankings—placing it in the 79th percentile in Surgery (Rank #115/551) and the 53rd percentile in Oncology (Rank #188/404). The journal is recognized for its rigorous exploration of current trends, innovations, and challenges in breast care, encompassing a wide scope from surgical techniques to oncological therapies. With a Q2 ranking in Oncology and a notable Q1 ranking in Surgery as of 2023, Breast Care not only contributes to the advancement of medical knowledge but also fosters interdisciplinary collaboration among healthcare professionals worldwide.

CANCER, published by Wiley, stands as a pivotal journal in the field of oncology and cancer research, boasting an impressive impact factor and consistently dynamic growth since its inception in 1948. With an ISSN of 0008-543X and an E-ISSN of 1097-0142, this esteemed journal is recognized for its rigorous peer-reviewed articles, making significant contributions to the understanding of cancer biology, treatment modalities, and clinical practices. CANCER holds a distinguished position in the academic community, securing its placement in the Q1 category for both cancer research and oncology, and ranks within the top percentiles on Scopus, indicating its high impact and relevance. The journal is particularly beneficial for researchers, professionals, and students seeking to stay abreast of the latest advancements in cancer science. By addressing essential research questions and providing pathways for new therapies, CANCER continues to play a crucial role in shaping the future of oncology and improving patient outcomes.

Onkologie is a peer-reviewed academic journal published by SPRINGER HEIDELBERG, focusing on the evolving fields of Oncology and Hematology. Established as a significant platform for the dissemination of research in these crucial areas of medicine, Onkologie aims to provide insights into the latest advancements, therapeutic strategies, and clinical practices that shape patient care in oncology and hematology. Despite its current placement in the Q4 category for both disciplines, this journal aspires to foster scholarly dialogues and enhance its contributions to the scientific community. The journal is based in Germany and encourages submissions that promote a deeper understanding of oncology's complex landscape, ensuring that researchers, clinicians, and students have access to a wealth of knowledge essential for clinical practice and further research. With an ISSN of 2731-7226 and E-ISSN of 2731-7234, Onkologie is committed to maintain high standards in publication and peer review, driving innovation and discovery in the fields it represents.

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.

ONCOLOGY-NEW YORK is a prominent journal dedicated to the field of oncology, published by UBM MEDICA. Since its inception in 1987, the journal has served as a pivotal platform for disseminating groundbreaking research and advancements in cancer treatment, research, and education. With an ISSN of 0890-9091 and an E-ISSN of 2767-7389, it stands as an accessible resource for professionals, researchers, and students alike. The journal currently holds impressive rankings, categorized within Q3 in Oncology and Q4 in Cancer Research for 2023, reflecting its commitment to high-quality research output and contributions to the field. Despite its challenges in Scopus rankings, positioned at #283/404 in Medicine: Oncology and #188/230 in Biochemistry, Genetics, and Molecular Biology: Cancer Research, ONCOLOGY-NEW YORK continues to primarily focus on innovative cancer therapies and emerging clinical research. The journal's ongoing dedication to enhancing knowledge and understanding in oncology makes it a vital resource for all stakeholders invested in combating cancer.

Radiation Oncology is a premier scholarly journal published by BMC, dedicated to advancing the field of oncology through innovative research and comprehensive reviews since its inception in 2005. With its Open Access model, the journal ensures that the latest findings in radiotherapy and cancer treatment are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and healthcare professionals. The journal has garnered an impressive reputation with prestigious rankings, achieving Q1 status in Radiology, Nuclear Medicine and Imaging and Q2 in Oncology as of 2023, reflecting its significant impact on the scientific community. In the Scopus rankings, it stands proud at Rank #61 in Radiology, Nuclear Medicine and Imaging, placing it in the top 81st percentile, and Rank #112 in Oncology at the 72nd percentile. With a converged publication plan extending through 2024, Radiation Oncology remains a vital resource for those dedicated to enhancing cancer treatment methodologies and outcomes.